14:00 |
Welcome |
Session 1 • 3D Modeling of Human Brain Disorders Chairs: Romina Aron Badin and Alessandro Fiorenzano |
|
14:15-14:45 |
Madeline Lancaster (MRC Laboratory of Molecular Biology, Cambridge, UK) New insights into human brain development from organoids |
14:45-15:15 |
Giuseppe Testa (Human Technopole, Neurogenomics Research Centre, Milan, Italy) Translating brain organoids endophenotypes: from mechanisms to scales |
15:15-15:45 |
Laurent Nguyen (University of Liège, Belgium) Cortical interneuron migration in the forebrain - Evo-devo perspectives |
15:45-16:00 |
Short talk selected from abstract Janko Kajtez (University of Copenhagen, Denmark) Injectable 3D microculture arrays enable intracerebral transplantation of mature neurons directly reprogrammed from patient fibroblasts |
16:00-16:30 |
Coffee break |
Session 2 • Cell Therapy & Clinical Trial For CNS Chairs: Eilís Dowd and Alexandra Durr |
|
16:30-17:00 |
Eilís Dowd (National University of Ireland, Galway, Ireland) Harnessing biomaterials to improve brain repair for Parkinson’s |
17:00-17:30 |
Gesine Paul-Visse (Lund University, Sweden) Transplantation of human embryonic-stem cell derived dopaminergic progenitors in Parkinson’s disease: first-in-human clinical trial design of STEM-PD |
17:30-18:00 |
Christelle Monville (Paris-Saclay University-Evry, France) Retinal Pigment Epithelial cells derived from human embryonic stem cells disposed on human amniotic membrane: an update on the French RP clinical trial |
18:00-18:15 |
Short talk selected from abstract Niamh Moriarty (The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia) Improving the functional integration of human pluripotent stem cell-derived neural grafts through environmental enrichment |
18:15-18:30 |
Short talk selected from abstract Edoardo Sozzi (Lund University, Sweden) Co-graft of dopamine progenitors and supporting cells to enhance cell-based therapy for Parkinson's Disease |
18:30-19:00 |
Data blitz 1 (5 talks of 3 min + discussion 15 min at the end) Emily A. Atkinson (UCL, London, UK) |
19:00-21:30 |
Get-together with posters |
Session 3 • Cell Engineering and Disease Modeling Chairs: Malú Gámez Tansey and Steve Pollard |
|
8:45-9:15 |
Michela Deleidi (Imagine Institute, Paris, France) Dissecting genetic brain disease at single cell resolution |
9:15-9:45 |
Antonella Consiglio (University of Barcelona, Spain) Novel insights into Parkinson’s disease through iPSC-based technology |
9:45-10:15 |
Alexandra Nicaise (University of Cambridge, UK) Neural stem cells as novel drivers of smouldering brain disease |
10:15-10:30 |
Short talk selected from abstract Merja Voutilainen (University of Helsinki, Finland) CDNF fragment passes the blood brain barrier protecting and restoring dopamine neurons animal models of Parkinson’s disease |
10:30-10:45 |
Short talk selected from abstract Karolina Pircs (HCEMM-Semmelweis University, Budapest, Hungary) Identification of novel targets with therapeutic potential in HD using a patient-derived induced neuronal model |
10:45-11:15 |
Coffee with posters always on display |
Session 4 • Immunology and Neuroinflammation Chairs: Simona Paladino and Stefano Pluchino |
|
11:15-11:45 |
Michael Heneka (University of Luxembourg, Luxembourg) Neuronal escape from neurodegeneration through innate immune interaction |
11:45-12:15 |
Malú Gámez Tansey (University of Florida, Gainesville, USA) Targeting chronic inflammation to reduce risks of neurodegenerative disease |
12:15-12:45 |
Rebecca Matsas (Hellenic Pasteur Institute, Athens, Greece) Beneficial and detrimental neuron-astrocyte interplay in p.A53T Parkinson’s disease |
12:45-13:00 |
Short talk selected from abstract Ranabir Chakraborty (Institut Pasteur, Paris, France) Tunneling nanotubes-mediated functional interactions between neuronal and microglial cells: a spotlight on neuroinflammation |
13:00-13:15 |
Short talk selected from abstract Francesca Boscia (University of Naples Federico II, Italy) Combined targeting of fatty acid amide hydrolase and melatonin receptors promotes neuroprotection and stimulates inflammation resolution |
13:15-14:30 |
Lunch |
Session 5 • Gene Therapy for CNS Chairs: Rebecca Matsas and Chiara Zurzolo |
|
14:30-15:00 |
Alexandra Durr (Sorbonne University, Paris, France) Presymptomatic phases of inherited neurodegeneration |
15:00-15:30 |
Steve Pollard (University of Edinburgh, UK) Synthetic super-enhancers enable selective expression of anti-cancer payloads for viral gene therapy in glioblastoma |
15:30-16:00 |
Patrick Yu-Wai-Man (Cambridge Centre for Brain Repair, UK) Therapies for mitochondrial blindness |
16:00-16:15 |
Short talk selected from abstract Martina Mazzocchi (University College Cork, Ireland) α-synuclein induces nuclear accumulation of HDAC5 and AAV-shHDAC5 is neuroprotective in an α-synuclein rat model of Parkinson’s disease |
16:15-16:45 |
Data blitz 2 (6 talks of 3 min + discussion 15 min at the end) Massimiliano Caiazzo (University of Naples Federico II, Italy) |
16:45-17:15 |
Coffee with posters always on display |
17:15-17:45 |
Special Session • Patient Advocacy Chair: Tilo Kunath Alison Williams (Edinburgh Branch of Parkinson's UK, UK) |
18:00-19:00 |
Session 6 • Session with Industry Chairs: Tilo Kunath and Francesco Gubinelli Kristian Kolind (Novo Nordisk) The cell journey - bringing a cell product safely and effectively into patients Marcus Yountz (BlueRock Therapeutics) Dopaminergic neuronal precursor cell therapy for Parkinson’s disease: background and 1 year results from a Phase 1 study of bemdaneprocel Theresa Mader (BioLamina) Imitate the natural cell matrix interactions for creating highly functional neural cells Philippe Hantraye (NeurATRIS) NeurATRIS: a large infrastructure for Translational Neuroscience |
19:00-19:30 |
NECTAR General Assembly |
20:30-23:00 |
Gala dinner |
Session 7 • Disease mechanisms Chairs: Michela Deleidi and Chiara Zurzolo |
|
8:45-9:15 |
Annalisa Buffo (University of Turin, Italy) Cell based approaches to reconstruct striatal circuits and promote functional recovery in a rat model of Huntington’s Disease: advances and challenge |
9:15-9:45 |
Mikael Simons (Institute of Neuronal Cell Biology, Munich, Germany) Mechanisms of remyelination in the CNS |
9:45-10:15 |
Susanne Wegmann (German Center for Neurodegenerative Diseases, Berlin, Germany) Liquid condensed Tau: a path to pathology |
10:15-10:30 |
Short talk selected from abstract Rossella Di Giaimo (University of Naples Federico II, Italy) Deciphering pathological mechanisms in EPM1 epilepsy: insights from extracellular vesicles |
10:30-10:45 |
Short talk selected from abstract Andrea Conte (University of Naples Federico II, Italy) Synpatojanin 1 (SYNJ1) dysfunction leads to autophagy dysregulation: potential impact on Parkinson’s disease |
10:45-11:15 |
Coffee break |
Session 8 • Clinical Trials Chairs: Antonella Consiglio and Anders Björklund |
|
11:15-11:30 |
Data blitz 3 (3 talks of 3 min + discussion 6 min at the end) Giuseppina Divisato (University of Naples Federico II, Italy) |
11:30-12:00 |
Malin Parmar (Lund Stem Cell Center, Sweden) Developing a stem cell based therapy for Parkinson’s disease; the interplay of experimental studies and translational efforts |
12:00-12:30 |
Gianvito Martino (Ospedale San Raffaele, Milan, Italy) Neural stem cells in neurological diseases: from biology to therapy |
12:30-13:00 |
Angelo Luigi Vescovi (University of Milan Bicocca, Italy) Neural stem cells: from the drawing board to ACT trials in neurological disorders... and back? |
13:00-13:30 |
Wrap up & Conference closure / poster prize |
The poster's maximum size is 80 x 120 cm (width x height).
Correct format... 
Wrong format...
P.1 Natalia Abate (Naples, Italy)
Human cerebral organoids as a tool to study synaptic plasticity alteration in EPM1
P.2 Giuseppina Amodio (Baronissi (SA), Italy)
The phosphoinositide phosphatase Synaptojanin-1 controls COPII vesicles assembly and trafficking in the early secretory pathway: implications for neurodegenerative diseases
P.3 Emily Atkinson (London, United Kingdom)
Design and synthesis of glial cell line-derived neurotrophic factor (GDNF) peptide mimetics for the treatment of Parkinson's Disease
P.4 Michela Ilaria Barbato (Edinburgh, United Kingdom)
Establishing a Progenitor Cell Bank of iPSC-derived cells poised for neural differentiation for the research community
P.5 Rebekah Bevans (Cork, Ireland)
Investigating the neuroprotective potenital of ZNHIT1 against alpha-synuclein-induced degeneration in in vitro models of relevance to Parkinson's Disease
P.6 Olga Teresa Bianciotto (Turin, Italy)
Analysis of the role of the synaptic adaptor protein p140Cap in iPSCs-derived human excitatory neurons
P.7 Helle Bogetofte Barnkob (Odense, Denmark)
Multi-omic analysis of guided and unguided forebrain organoids reveal differences in cellular composition and metabolic profiles
P.8 Jana Bonsberger (Lund, Sweden)
Patient-derived dopamine neurons for autologous cell replacement therapy for Parkinson's disease
P.9 Andreas Bruzelius (Lund, Sweden)
A three-dimensional co-culture model to generate human subtype specific interneurons
P.10 Massimiliano Caiazzo (Naples, Italy)
Cell engineering approaches for in vitro neural modeling
P.11 Andrew Chai (Edinburgh, United Kingdom)
Investigating the role of alpha-synuclein in neuronal innate immunity and its role in the interferon response pathway
P.12 Laura Colombo (Paris, France)
A human derived organ-on-chip model to study the role of LRRK2 in intestinal inflammation
P.13 Giulia Comini (Galway, Ireland)
The beneficial effect of a GDNF and BDNF-enriched collagen hydrogel on the differentiation of iPSC-derived dopaminergic progenitors in cyclosporine immunosuppressed rats
P.14 Sara Corsi (Lund, Sweden)
Exploring α-synuclein pathology development and microglia response in stem cell-derived transplants in a humanized xenograft model of PD
P.15 Laura De Rosa (Naples, Italy)
Early dysregulation of endosomal pathway in Down syndrome: potential impact in neuropathogenesis
P.16 Giuseppina Divisato (Naples, Italy)
Sorbitol dehydrogenase deficiency impairs mitochondrial homeostasis in patients affected by CMT2/dHMN
P.17 Tyra Fraser (Parkville, Australia)
Using engineered iPSC-reporter lines to characterise anatomical integration of transplanted human dopamine neurons
P.18 María García Garrote (Lund, Sweden)
Unravelling the role of vascular leptomeningeal cells (VLMCs) in hPSC-derived grafts for Parkinson’s Disease
P.19 Carmela Giachino (Paris, France)
The role of LRRK2 in intercellular communication
P.20 Gabriela Gomez Gonzalez (Orbassano (TO), Italy)
Exploring striatal graft functions through in vivo calcium recordings in a rat model of Huntington's Disease
P.21 Cinta Gomis López (Barcelona, Spain)
CD200-based cell sorting generates homogeneous subpopulations of transplantable striatal neuroblasts
P.22 Holly Gregory (London, United Kingdom)
Local immunosuppression using tacrolimus microparticles for cell transplantation in treatment of Parkinson’s disease
P.23 Francesco Gubinelli (Munich, Germany)
Investigating the role of DJ-1 mutation in iron dysregulation and neuronal damage in Parkinson’s disease
P.24 Mette Habekost (Lund, Sweden)
Direct reprogramming of human stem cell-derived glia into dopaminergic neurons for Parkinson's Disease therapy
P.25 Leonie Heger (Munich, Germany)
The role of synaptic mitochondrial dysfunction in dopamine oxidation in Parkinson’s disease
P.26 Srisaiyini Kidnapillai (Lund, Sweden)
Integration and maturation of transplanted human GABAergic interneurons derived from human glial progenitor cells into the mouse medial prefrontal cortex
P.27 Mariah Lelos (Cardiff, United Kingdom)
Generating a hESC-derived medium spiny neuron cell therapy product for clinical application
P.28 Ivan Lombardi (Milan, Italy)
Evaluation of hNSCs safety and efficacy upon intracerebroventricular transplantation in a preclinical model of ALS
P.29 Theresa Mader (Sundbyberg, Sweden)
Improved neural cell functionality by imitating the natural cell-matrix interactions in cellular models and translational research
P.30 Raquel Martínez Curiel (Lund, Sweden)
Human cortical neurons rapidly generated by direct ES cell programming integrate into stroke-injured rat cortex
P.31 Bengt Mattsson (Lund, Sweden)
A stereotaxic atlas of the nude rat brain allowing more precise targeting of human-to-rat xenografts
P.32 Kaushik Narasimhan (Galway, Ireland)
Assessing biomaterial microcarriers for sustained delivery of GDNF & BDNF in the context of enhancing cell-based brain repair in the Parkinsonian rat brain
P.33 Nikolina Ntinou (Patras, Greece)
Dissecting the impact of chronic stress on dentate gyrus plasticity in Tau brain pathology
P.34 Adam O'Mahony (Cork, Ireland)
The small molecule histone deacetylase inhibitor TMP269 is neuroprotective in 6-hydroxydopamine models of Parkinson’s Disease through a BMP Smad dependent pathway
P.35 [WITHDRAWN]
P.36 Francesca Palese (Paris, France)
Perturbation of membrane lipid composition and protein spreading between neurons
P.37 Sara Palma Tortoss (Lund, Sweden)
Development and validation of novel cell-based therapeutic strategies for human brain regeneration
P.38 Florentia Papastefanaki (Athens, Greece)
Cell-intrinsic pathological characteristics in p.A53T-αSyn iPSC-derived astrocytes from Parkinson’s disease patients
P.39 Tommy Patton (Galway, Ireland)
Sequential exposure to AAV-α-synuclein and FN075 as an approach to modelling Parkinson’s disease in the rat
P.40 Nicolas Prudon (Pessac, France)
Microtissue cell therapy for Parkinson’s disease: scale-up in bioreactors and latest in vivo results
P.41 Marta Ribodino (Orbassano (TO), Italy)
Functional circuit reconstruction of transplanted striatal neurons into a rodent model of Huntington's Disease
P.42 Jose Salazar Campos (Munich, Germany)
Unraveling the contribution of oligodendrocytes to Parkinson's disease pathology
P.43 Alrik Schörling (Copenhagen, Denmark)
APCDD1 outperforms other dopaminergic cell surface markers in benchmarking study
P.44 Christina Stamouli (Lund, Sweden)
Investigating a gene regulatory network and developmental trajectory for promoting parvalbumin neuronal fate during reprogramming
P.45 Petter Storm (Lund, Sweden)
Molecular lineage tracing of stem cell derived dopamine grafts in vivo reveals a shared origin of all graft-derived cells
P.46 Valeria Valente (Paris, France)
TDP-43 protein delocalization and spreading: new molecular insights in Amyotrophic lateral sclerosis pathogenesis and progression
P.47 Zhijun Wang (Edinburgh, United Kingdom)
Visualizing mitochondrial dysfunction in human neurons and cardiomyocytes with mitochondrial stress reporter iPSC lines
P.48 Rachel Wise (Munich, Germany)
Iron dyshomeostasis and dopamine oxidation in iPSC-derived dopaminergic neurons from Beta-propeller Protein-Associated Neurodegeneration (BPAN) patients